Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COVI-VAC as a Booster Dose in Previously Vaccinated Adults
NCT05233826Phase 1Completed
- Sponsor
- Codagenix
- Start
- Apr 2022
- Primary completion
- Jul 2022
- Modality
- Live Attenuated Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of COVI-VAC in coronavirus disease 2019 (COVID-19), sponsored by Codagenix. Primary endpoints: Humoral Immunogenicity at Day 181 and Humoral Immunogenicity measured by neutralizing antibodies at Day 181. Started Apr 2022; status: completed.
02
Drugs
COVI-VAC
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05233826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05233826.